DUBLIN, June 6, 2016 /PRNewswire/ -- Actress,
producer and model Kate Bosworth is
partnering with Allergan plc (NYSE: AGN), a leading global
pharmaceutical company, to unveil the new ACZONE® (dapsone) Gel,
7.5% and share her personal experience with acne. ACZONE® Gel, 7.5%
is a new prescription topical treatment for acne in patients 12
years of age and older, with just once-a-day
application.1 At an exclusive event hosted in
New York City, Kate teamed up with
nationally-renowned dermatologist, Joshua
Zeichner, MD, to discuss the complexities behind the most
common chronic skin condition in the U.S.2 and steps to
help manage acne, from what goes in the body to what goes on the
skin.
"While one of my favorite parts of the job is being able to
travel the world, my on-the-go schedule can encounter several
inconsistencies, like lack of sleep or environmental
changes," Kate says.3,4 "Finding a balance with a
healthy lifestyle and consistent skin care regimen has helped me
tremendously. I visited my dermatologist and was prescribed
ACZONE® Gel, 7.5% to treat my acne."
Acne affects 40 to 50 million men and women in the U.S. alone,
and nearly 85% of people between the ages of 12 and 24 struggle
with acne at some point in their lives.2 Even though
acne is more common in teenagers, adult acne may be more common
than previously thought; about one out of three people seeking
treatment for acne are 25 years or older.5,6 Acne is a
multifactorial disease—environmental factors, hormonal
fluctuations, medications, heredity/genetics, emotional stress and
diet may all contribute to acne.2
"We are very fortunate to be partnering with Kate for this event
to launch the new ACZONE® Gel, 7.5%," says Jag Dosanjh, Senior Vice
President, Medical Dermatology at Allergan. "Through Kate's story,
we hope to show acne sufferers that they are not alone with acne on
their mind and encourage them to visit a dermatologist to find the
right treatment option and help have less acne to think about."
"It is not uncommon for women to develop acne for the first time
as an adult, in their 20s or 30s.7 I always remind my
patients that acne is not just an issue teenagers suffer
with. While there is no cure, it can be managed with the
right treatment regimen," said Joshua
Zeichner, NYC-based Dermatologist. "ACZONE® Gel, 7.5% was
approved by the U.S. Food and Drug Administration (FDA) in
February 2016. In the largest pivotal
trial program conducted for FDA approval of a topical acne drug,
once-daily application ACZONE® Gel, 7.5% was clinically proven to
be effective and safe in treating inflammatory and comedonal acne
in 12 weeks." 1
For more information or to find a dermatologist, please visit
www.aczone.com.
PHOTO CAPTION: Actress, Producer and Model Kate Bosworth at the
ACZONE® (dapsone) Gel, 7.5% Launch Event in New York City
PHOTO CREDIT: Jennifer Graylock,
Getty Images
Approved Use
ACZONE® (dapsone) Gel, 7.5% is a prescription
medicine used on the skin (topical) to treat acne in people 12
years and older.
Important Safety Information
Tell your doctor about all of your medical conditions, including
if you have; glucose-6-phosphate dehydrogenase deficiency (G6PD) or
higher than normal levels of methemoglobin in your blood
(methemoglobinemia).
Talk to your doctor about any medications you're using including
topical benzoyl peroxide (BPO). Use of BPO with ACZONE®
Gel may cause your skin and facial hair to temporarily turn yellow
or orange at the site of application.
ACZONE® Gel, 7.5% may cause serious side effects,
including:
- a decrease of oxygen in your blood caused by a certain type of
abnormal red blood cell (methemoglobinemia). If your lips,
nail beds or the inside of your mouth turns grey or blue, stop
using ACZONE® Gel, 7.5% and get medical help right
away.
- a breakdown of red blood cells (hemolytic anemia) for some
people with G6PD deficiency using ACZONE® Gel, 7.5%.
Stop using ACZONE® Gel, 7.5%, and call your doctor right
away if you get any of the following signs and symptoms: back pain,
breathlessness, tiredness/weakness, dark-brown urine, fever, or
yellow or pale skin.
The most common side effects of ACZONE® Gel, 7.5% are
dryness and itching of the skin being treated.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
Please click here for the full Product Information.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin,
Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the
world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an
industry leader in research and development, with one of the
broadest development pipelines in the pharmaceutical industry and a
leading position in the submission of generic product applications
globally.
With commercial operations in approximately 100
countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives.
For more information, visit Allergan's website
at www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing
trends and information as of the date of this release. Except as
expressly required by law, Allergan disclaims any intent
or obligation to update these forward-looking statements. Actual
results may differ materially from Allergan's current
expectations depending upon a number of factors
affecting Allergan's business. These factors include,
among others, the difficulty of predicting the timing or outcome
of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or
delays in manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not
limited to Allergan's Annual Report on Form 10-K for the
year ended December 31, 2015 (certain of such periodic
public filings having been filed under the "Actavis plc" name).
Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
1 ACZONE® (dapsone) Gel 7.5% U.S. Prescribing
Information
2 American Academy of Dermatology. "Acne." Available
online at: https://www.aad.org/media/stats/conditions Last accessed
on April 28, 2016
3 Glozier, N. et al. Short Sleep Duration in
Prevalent and Persistent Psychological Distress in Young Adults:
The DRIVE Study, 2010; 33 (9); 1139-1145
4 American Academy of Dermatology, "Adult acne."
Available online at:
https://www.aad.org/public/diseases/acne-and-rosacea/adult-acne
Last accessed on December 7, 2015
5 American Academy of Dermatology. Acne: who gets and
causes. Available at:
https://www.aad.org/public/diseases/acne-and-rosacea/acne. Accessed
January 19, 2016.
6 Yentzer BA, Hick J, Reese EL, Uhas A, Feldman SR,
Balkrishnan R. Acne vulgaris in the
United States: a descriptive epidemiology. Cutis.
2010;86(2):94–99.
7 American Academy of Dermatology. "Acne and
Rosacea." Last updated June 8,
2011
APC45VP16
CONTACTS:
Media:
Mark Marmur
(973) 906-1526
Ember Garrett
(714) 246-3525
Photo -
http://photos.prnewswire.com/prnh/20160605/375614
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kate-bosworth-partners-with-allergan-to-celebrate-launch-of-aczone-dapsone-gel-75-in-new-york-city-300279936.html
SOURCE Allergan plc